CONSOLIDATED ENTITIES AND ACQUISITIONS - Entasis Therapeutics Holdings, Inc. (Details) $ / shares in Units, $ in Thousands			1 Months Ended	3 Months Ended	12 Months Ended
	Jul. 11, 2022 USD ($)	Feb. 17, 2022 USD ($) $ / shares	Feb. 28, 2023 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2023 USD ($) Director	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Subsidiary or Equity Method Investee [Line Items]
Total debt					$ 453,500	$ 549,704
Net loss attributable to noncontrolling interest					179,722	213,921	$ 265,854
Net loss attributable to noncontrolling interests					$ 0	(6,341)	$ (102,983)
Entasis Therapeutics Holdings Inc
Subsidiary or Equity Method Investee [Line Items]
Number of investee's board members which may be designated by the Company | Director					2
Remeasurement loss				$ 7,800
Payment towards convertible promissory note	$ 0
Measurement period adjustments for change in value of goodwill			$ 1,200			(4,700)
Measurement period adjustments for change in estimated purchase price						(1,400)
Measurement period adjustments for change in value of noncontrolling interests						1,700
Measurement period adjustments for change in value of intangible assets			(800)			2,500
Measurement period adjustments increase decrease in deferred tax liabilities			$ 400
Noncontrolling interests		$ 38,500
Net loss attributable to noncontrolling interest						$ 13,600
Entasis Therapeutics Holdings Inc | Consolidated Investees
Subsidiary or Equity Method Investee [Line Items]
Equity method investment ownership percentage		59.90%
Entasis Therapeutics Holdings Inc | Securities purchase agreement | Convertable promissory note
Subsidiary or Equity Method Investee [Line Items]
Total debt		$ 15,000
Debt Instrument, annual interest rate		0.59%
Debt instrument maturity date		Aug. 18, 2022
Conversion price (dollars per share) | $ / shares		$ 1.48
Entasis Therapeutics Holdings Inc | Common stock
Subsidiary or Equity Method Investee [Line Items]
Fair value of equity securities		$ 64,500
Entasis Therapeutics Holdings Inc | Warrants
Subsidiary or Equity Method Investee [Line Items]
Fair value of equity securities		$ 31,400